With a growing number of complex cell and gene therapies approved globally, mostly for rare disease populations, manufacturers are looking at how to make these products more accessible by delivering available treatments through a greater number of health care centers and by developing new treatments for larger patient populations.
Manufacturers Eye Challenges Of Broadening Cell And Gene Therapy Access
Potential Expansion From Academia To Community
With more advanced therapies gaining approval, companies at ARM’s Cell and Gene Meeting on the Mesa considered hurdles to making their products more broadly available and developing them for larger indications.
More from Gene Therapies
More from Advanced Therapies
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.
• By
Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma
• By
The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.